Susquehanna Fundamental Investments LLC Buys New Shares in Definitive Healthcare Corp. (NASDAQ:DH)

Susquehanna Fundamental Investments LLC purchased a new stake in shares of Definitive Healthcare Corp. (NASDAQ:DH - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 287,409 shares of the company's stock, valued at approximately $1,181,000. Susquehanna Fundamental Investments LLC owned approximately 0.25% of Definitive Healthcare at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of the business. Two Sigma Securities LLC purchased a new stake in Definitive Healthcare in the 4th quarter worth approximately $56,000. Price T Rowe Associates Inc. MD raised its holdings in shares of Definitive Healthcare by 20.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 20,572 shares of the company's stock worth $85,000 after acquiring an additional 3,496 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in Definitive Healthcare by 1.3% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,863,912 shares of the company's stock valued at $7,661,000 after purchasing an additional 23,410 shares during the last quarter. Canada Pension Plan Investment Board grew its stake in Definitive Healthcare by 18.1% in the fourth quarter. Canada Pension Plan Investment Board now owns 29,300 shares of the company's stock valued at $120,000 after purchasing an additional 4,500 shares in the last quarter. Finally, Marshall Wace LLP increased its position in Definitive Healthcare by 160.8% in the 4th quarter. Marshall Wace LLP now owns 32,282 shares of the company's stock worth $133,000 after purchasing an additional 19,904 shares during the last quarter. 98.67% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on DH. The Goldman Sachs Group reduced their price target on Definitive Healthcare from $4.50 to $3.00 and set a "neutral" rating for the company in a report on Tuesday, March 4th. Barclays dropped their price target on shares of Definitive Healthcare from $4.00 to $3.00 and set an "underweight" rating on the stock in a research note on Monday, March 3rd. Finally, Needham & Company LLC restated a "hold" rating on shares of Definitive Healthcare in a report on Thursday, January 16th. Two analysts have rated the stock with a sell rating, seven have given a hold rating and three have assigned a buy rating to the company's stock. Based on data from MarketBeat, Definitive Healthcare presently has a consensus rating of "Hold" and a consensus target price of $5.35.

Definitive Healthcare Stock Performance

Definitive Healthcare stock traded up $0.09 on Wednesday, reaching $2.74. 93,511 shares of the stock were exchanged, compared to its average volume of 851,745. The stock has a market cap of $295.28 million, a PE ratio of -0.88, a PEG ratio of 4.06 and a beta of 1.48. The firm has a fifty day moving average price of $2.70 and a two-hundred day moving average price of $3.90. Definitive Healthcare Corp. has a twelve month low of $2.15 and a twelve month high of $7.47. The company has a current ratio of 2.49, a quick ratio of 2.49 and a debt-to-equity ratio of 0.33.

Definitive Healthcare (NASDAQ:DH - Get Free Report) last announced its earnings results on Thursday, February 27th. The company reported $0.03 earnings per share for the quarter, missing the consensus estimate of $0.07 by ($0.04). The business had revenue of $62.29 million for the quarter, compared to the consensus estimate of $60.60 million. Definitive Healthcare had a negative net margin of 142.38% and a positive return on equity of 1.76%. Sell-side analysts anticipate that Definitive Healthcare Corp. will post 0.16 EPS for the current year.

About Definitive Healthcare

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution.